Sorry, you need to enable JavaScript to visit this website.
Search
April 8, 2022

Protection of A Third COVID-19 mRNA Vaccine Dose Against Asymptomatic and Symptomatic SARS-CoV-2 Variant Infections

Authors

Lauren E.W. Olsho, PhD, Laura J. Edwards, MPH, Brian Sokol, MSPA, Abt Global; Sarang K. Yoon, DO, MOH, Kurt T. Hegmann, MD, MPH, Matthew S. Thiese, PhD, MSPH, University of Utah Health; Jefferey L. Burgess, MD, MS, MPH, Katherine Ellingson, PhD, Karen Lutrick, PhD, University of Arizona; Alberto J. Caban-Martinez, DO, PhD, Natasha Schaefer Solle, PhD, John M. Jones, B.S., University of Miami; Harmony Tyner, MD, St. Luke’s Regional Health Care System (Duluth, MN); Manjusha Gaglani, MBBS, Kayan Dunnigan, MPH Spencer Rose, B.S. Baylor Scott & White Health; Allison Naleway, PhD, Holly Groom, MPH, Jennifer Kuntz, PhD, Kaiser Permanente Northwest; Ashley L. Fowlkes, ScD, Mark G. Thompson, PhD, Young M. Yoo, MSPH, Centers for Disease Control and Prevention (CDC)

In a letter to the editor of the New England Journal of Medicine, researchers from Abt Global and their partners reported that a study of essential and frontline workers showed that three doses of COVID-19 vaccine are more effective than two. The vaccines are less effective against Omicron than against the Delta variant but are effective against both. 

The study for the Centers for Disease Control and Prevention (CDC) involved 3,241 essential and frontline workers who sent in nasal swabs weekly from August 26, 2021 until January 22, 2022, regardless of whether they had symptoms. Effectiveness against the Delta variant was 65 percent after two doses and 91 percent after three. The results were similar to a study in which participants received medical care because they had symptoms.

Vaccine effectiveness against Omicron infection for three doses (60 percent) was higher than for two doses (46 percent), but still substantially lower than three-dose effectiveness against Omicron reported elsewhere where individuals sought medical attention for their symptoms (82-90 percent). Lower effectiveness against mild or asymptomatic Omicron infection dovetails with data suggesting the Omicron variant is less severe. The results show continued effectiveness against clinically severe outcomes related to both variants.

The authors’ findings and conclusions do not necessarily represent the CDC’s views.


Read More

COVID-19 in North America

Multi-site study of communities with PFAS-contaminated drinking water: Methods, demographics, and PFAS serum concentrations

Presents findings from a multi-site study examining the relationship between PFAS-contaminated drinking water and PFAS levels in residents’ blood across the U.S.

Learn More
Publication

Building an AI-Enabled Platform for Federal Data Analysis

Abt Digital Solutions built the Dynamic Soils Hub to modernize how USDA analyzes and applies soil data for conservation impact.

Learn More
Impact Brief

From Experiment to Action: How Medicare is Transforming Cancer Care

Cancer is one of the most expensive and complex conditions to treat. But can better care for cancer patients also cost less?

Learn More
Impact Brief

Coastal Resilience Powered by Open Data and Modern Tools

For the Department of the Interior, streamlined data access and user-friendly tools that strengthen coastal protection, marine minerals access, and environmental resilience. ​

Learn More
Impact Brief